U.S. Insurance Stock News

Taysha Gene Therapies recently reported that the FDA cleared it to begin the ASPIRE clinical trial of TSHA-102, its investigational gene therapy for Rett syndrome, and also granted inducement RSUs and stock options to four new employees under Nasdaq Listing Rule 5635(c)(4). This regulatory milestone for TSHA-102, coupled with preparations for potential commercialization, highlights how central Rett syndrome has become to Taysha’s business focus. Next, we’ll examine how FDA clearance to...

Wondering if Cirrus Logic at around US$154.82 is giving you fair value or asking too much for its growth story? This article breaks that question down in plain terms. The stock has shown strong recent returns, with 5.2% over 7 days, 15.6% over 30 days, 29.4% year to date, 71.6% over 1 year, 73.4% over 3 years, and 84.2% over 5 years, which naturally raises questions about how much optimism is already in the price. Recent coverage has focused on Cirrus Logic as part of wider discussions...

Aon recently expanded its digital infrastructure capabilities by appointing Stephen Fox as Managing Director and, earlier, upgraded its Radford McLagan Compensation Database with AI-specific job families and tools to better assess fast-evolving AI roles worldwide. Together, these moves show Aon deepening its role at the intersection of risk, capital, and AI-enabled workforce planning for large-scale, technology-focused clients. Now we’ll examine how Aon’s AI-focused compensation enhancements...

If you are wondering whether DoubleVerify Holdings is attractively priced or still too expensive, this breakdown will help you frame the current share price against what you might actually be paying for. The stock last closed at US$10.09, with returns of 3.2% over the past week, a 6.6% decline over the past month, and a 24.5% decline over the past year, which may have changed how the market is viewing its risk and reward trade off. Recent coverage has focused on DoubleVerify Holdings as an...

In early April 2026, Applied Materials introduced two chipmaking systems for 2nm and Angstrom-era logic chips that use atomic-level deposition to improve transistor isolation and metal gate formation for advanced AI processors. By solving key manufacturing bottlenecks in Gate-All-Around transistor structures and already seeing adoption by leading foundries, these tools deepen Applied Materials’ role at the core of next-generation AI chip production. Next, we’ll examine how this push into...

On March 16, 2026, McGill and Partners announced a collaboration with American International Group to apply agentic artificial intelligence to manage capacity deployment in the subscription market, supported by AIG’s US$1.60 billion commitment to McGill’s specialty gross premiums written portfolio, representing 25% of AIG’s capacity. This partnership highlights how AIG is tying advanced AI tools directly to underwriting decisions and capital allocation, potentially reshaping how it...

Wondering whether Vistra at around US$155.89 still offers value or if most of the opportunity is already priced in? This breakdown helps you size that up with numbers rather than hype. The stock price has moved 1.3% over the last 7 days, while the 30 day and year to date returns of a 4.7% decline and 5.7% decline sit against a 32.8% gain over the past year and a very large 3 year and 5 year return profile. Recent coverage has focused on Vistra as a major US utilities player, with attention...

In recent days, commentary around the Pacer Data & Infrastructure Real Estate ETF and Jefferies’ views on SBA Communications has highlighted American Tower’s long history of consistent dividend increases, stable long-term tower leases and comparatively strong platform quality within the infrastructure REIT space. Amid questions over competitors’ leverage, dividend cuts and potential sale processes, American Tower is being framed as a relatively dependable income and infrastructure exposure...

Vertex Pharmaceuticals (VRTX) just received U.S. FDA approval to expand the use of its cystic fibrosis drugs ALYFTREK and TRIKAFTA. This regulatory milestone widens treatment eligibility and puts the stock back in focus for many investors. See our latest analysis for Vertex Pharmaceuticals. The FDA label expansions arrive after a softer run in the share price, with a 90 day share price return of a 5.48% decline and a 1 year total shareholder return of a 7.96% decline. However, a 5 year total...

Investors may be wondering if Madrigal Pharmaceuticals at around US$519.75 a share is still offering value, or if the easy gains are already behind it. The stock has been volatile recently, with a 1.9% decline over the last week, a 20.0% return over 30 days, a 12.5% decline year to date, and a 65.6% return over the past year, alongside very large gains over 5 years. Recent headlines around Madrigal have focused on its position in the biotech space and the market's shifting expectations for...

In late March 2026, Oklo Inc. and Sweden’s Blykalla AB expanded their transatlantic partnership to collaborate on fast reactor commercialization, with Blykalla planning US$100–200 million of potential U.S. investments and committing 30–40 engineers to support Oklo’s DOE‑authorized reactor pilot and related technical workstreams. This deeper collaboration not only aims to speed Oklo’s technology development and enable fast‑neutron irradiation testing, but also highlights how external capital...

Seven Democratic U.S. senators have launched a federal investigation into an IRS tax credit payout to Cheniere Energy related to its LNG export vessels. The probe questions whether Cheniere properly qualified for alternative fuel tax credits and how those credits were applied. The outcome could influence how tax rules are interpreted for LNG infrastructure and similar energy projects. For investors watching Cheniere Energy (NYSE:LNG), the scrutiny comes as the stock trades at $275.21, with...

Recent news highlights Kinder Morgan’s past record net income and adjusted EBITDA, a roughly US$10.00 billion, mostly natural gas‑focused project backlog, and highly fee-based or hedged cash flows that are drawing attention ahead of its upcoming earnings report. Investors are especially focused on how Kinder Morgan’s large, long-term contracted natural gas infrastructure tied to power generation and LNG exports could underpin its cash flow stability as analyst earnings estimates...

If you are wondering whether Kratos Defense & Security Solutions is still good value after a strong run, this article breaks down what the current share price might be implying about the company. The stock last closed at US$74.46, with returns of 10.6% over 7 days, a 16.3% decline over 30 days, a 6.1% decline year to date, and a 1 year return of 134.8%, alongside a 3 year return of 468.8% and a 5 year return of 164.5%. These moves sit against a backdrop of ongoing investor attention on...

Recent performance snapshot DraftKings (DKNG) has seen mixed share performance recently, with a roughly 4.3% move over the past day and an 8.0% gain over the past week, contrasting with weaker returns over the past month and the past 3 months. See our latest analysis for DraftKings. The recent 1-day share price return of 4.31% and 7-day gain of 8.03% come after a much weaker 90-day share price return of a 33.46% decline and a 1-year total shareholder return of a 33.20% decline, suggesting...

Sterling Infrastructure recently reported strong quarterly results, with revenue and earnings rising sharply year over year, supported by significant demand in its E-Infrastructure segment and a record project backlog reported before today’s date. The company’s net cash position, ongoing share repurchases and acquisitions, and Zacks Rank #1 (Strong Buy) highlight how improved cash generation and analyst confidence are reinforcing its business momentum. Now we’ll examine how this record...

What the latest move in Antero Resources (AR) might mean for investors Antero Resources (AR) recently closed at US$39.17, with the stock showing mixed short term performance, including a small return over the past month and a stronger gain across the past 3 months. See our latest analysis for Antero Resources. While the 1 day and 7 day share price returns of 3.66% and 4.14% are weaker, a 21.72% 3 month share price return and a 313.62% 5 year total shareholder return indicate that momentum has...

Lattice Semiconductor (LSCC) is back on traders’ radar after a sharp move higher tied to a broad semiconductor rally, following the reopening of the Strait of Hormuz and easing U.S. Iran tensions. See our latest analysis for Lattice Semiconductor. Beyond today’s move, LSCC has been on a strong run, with a 30-day share price return of 17.58% and a 1-year total shareholder return of 129.46%. This performance reflects growing interest in its AI, robotics, and security focused FPGA exposure after...

Bloom Energy recently appointed Simon Edwards as Chief Financial Officer, effective April 13, 2026, while Maciej Kurzymski continues as Principal Accounting Officer, and the company was named to Newsweek’s 2026 list of America’s Most Trustworthy Companies in the Energy & Utilities category. These developments, alongside rapid growth in AI data center power demand and Bloom’s expanding backlog of long-term fuel cell contracts, highlight how the company is positioning itself as a key provider...

Vertical Aerospace (NYSE:EVTL) has drawn fresh attention after outlining a comprehensive financing package of up to US$775 million in senior secured convertible notes, Series A preferred shares, and an equity line of credit. See our latest analysis for Vertical Aerospace. After the financing announcement, the 1 day share price return of 13.76% and 7 day share price return of 9.73% contrast with a 30 day share price return decline of 39.07% and a 1 year total shareholder return decline of...

Investors may be wondering if National Energy Services Reunited at US$24.05 is still offering value after such a strong run, or if the easy part of the move is already behind it. The stock has delivered returns of 9.1% over the last 7 days, 16.0% over 30 days, 52.3% year to date and 286.7% over 1 year. This naturally raises questions about how its current price lines up with underlying value. Recent attention on National Energy Services Reunited has focused on its position within the energy...

Investors may be wondering whether Halliburton at around US$37.80 is still offering value after a strong run, or if most of the opportunity is already priced in. The stock has been volatile in the short term, with a 0.5% decline over the last week. However, the 30-day return of 9.1%, year-to-date return of 27.7% and 1-year return of 76.0% mean many investors are reassessing both upside potential and risk. Recent coverage of Halliburton has focused on its role as a major energy services...

If you are wondering whether T1 Energy at US$4.17 is starting to look attractive or still carries hidden risks, the key is to line up its price against a few clear valuation checks. The share price has seen sharp swings, with a 253.4% return over the last year, while more recent periods show a 6.9% decline over 7 days, a 41.8% decline over 30 days, and a 46.8% decline year to date. Recent moves have put T1 Energy back on many watchlists, as investors reassess what the latest price action...

In recent months, SouthState Bank reported Q4 2025 results that management described as strong, featuring earnings per share growth of more than 30%, double-digit tangible book value growth, an 11% dividend increase, and the repurchase of 2 million shares, alongside Board approval for an additional 5.56 million-share buyback authorization. While Tudor Investment Corp sharply reduced its position and some banks adjusted their research views, SouthState’s larger repurchase plan underscores...